Sigma-1 and Epilepsy

Published research to date related to the Sigma-1 protein and Epilepsy has been conducted with compounds not developed by Advantx Pharmaceuticals Inc. Our therapeutic candidate ADV127 for Focal Epilepsy is the first truly selective, pharmaceutical-grade compound in development targeting the Sigma-1 receptor with a molecule clearly agonist, and far superior in potency, selectivity, safety, and efficacy to all others tested to date.


Sigma-1 receptor and seizures

By Edijs Vavers, Liga Zvejniece, and Maija Dambrova Excerpt from the article published in Pharmacological Research, Volume 191, May 2023, 106771, ISSN 1043-6618, DOI: Editor’s Highlights Abstract Over the last decade, sigma-1 receptor (Sig1R) has been recognized as a valid target for the treatment of seizure disorders and seizure-related comorbidities. Clinical trials with Sig1R […]

Gender and Neurosteroids: Implications for Brain Function, Neuroplasticity, and Rehabilitation

By Loredana Raciti, Caterina Formica, Gianfranco Raciti, Angelo Quartarone, and Rocco Salvatore Calabrò Excerpt from the article published in the International Journal of Molecular Sciences. 2023; 24(5):4758. 1 March 2023. DOI: Editor’s Highlights Abstract Neurosteroids are synthesized de novo in the nervous system; they mainly moderate neuronal excitability, and reach target cells via the […]

Neurexin1α knockout rats display oscillatory abnormalities and sensory processing deficits back-translating key endophenotypes of psychiatric disorders

By Philipp Janz, Marie Bainier, Samuel Marashli, Philipp Schoenenberger, Miguel Valencia, and Roger L. Redondo Excerpt from the article published in Translational Psychiatry volume 12, Article number: 455, 28 October 2022, DOI: Editor’s Highlights Neurexins (NRXNs) are a large family of cell adhesion proteins that play a central role in synapse maturation and organization […]

Adenosine A2A receptors control synaptic remodeling in the adult brain

By Xinli Xu, Rui O. Beleza, Francisco Q. Gonçalves, Sergio Valbuena, Sofia Alçada-Morais, Nélio Gonçalves, Joana Magalhães, João M. M. Rocha, Sofia Ferreira, Ana S. G. Figueira, Juan Lerma, Rodrigo A. Cunha, Ricardo J. Rodrigues, and Joana M. Marques Excerpt from the article published in Scientific Reports 12, 14690, 29 August 2022, DOI: Editor’s […]

Interactome overlap between risk genes of epilepsy and targets of anti-epileptic drugs

By Yu-Qin Lv, Xing Wang, Yu-Zhuang Jiao, Yan-Hua Wang, Na Wang, Lei Gao, and Jing-Jun Zhang Excerpt from the article published in Plos One, August 25, 2022, DOI: Editor’s Highlights Epilepsy is a widespread chronic nervous system disease, which affects about 70 million people all over the world. With the development of sequencing technology, […]

Understanding the Role of Glia-Neuron Communication in the Pathophysiology of Epilepsy: A Review

By Peng Chen, Fuchao Chen, and Benhong Zhou Excerpt from the article published in  Journal of Integrative Neuroscience (JIN) 2022, 21(4), 102. Published: 30 May 2022. DOI: Editor’s Highlights Epilepsy is a prevalent, chronic, and severe neurological disorder characterized by abnormal hypersynchrony of a large population of neurons. It is widely assumed that there is an […]

Biallelic CACNA2D1 loss-of-function variants cause early-onset developmental epileptic encephalopathy

By Shehrazade Dahimene, Leonie von Elsner, Tess Holling, Lauren S. Mattas, Jess Pickard, Davor Lessel, Kjara S. Pilch, Ivan Kadurin, Wendy S. Pratt, Igor B. Zhulin, Hongzheng Dai, Maja Hempel, Maura R. Z. Ruzhnikov, Kerstin Kutsche, Annette C. Dolphin Excerpt from the article published in Brain, awac081, Editor’s Highlights Bi-allelic variants in CACNA2D1, encoding alpha2delta-1 […]

Alterations in Excitatory and Inhibitory Synaptic Development Within the Mesolimbic Dopamine Pathway in a Mouse Model of Prenatal Drug Exposure

By Taylor Boggess, James C. Williamson, Ethan B. Niebergall, Hannah Sexton, Anna Mazur, Richard D. Egleton, Lawrence M. Grover, and W. Christopher Risher Excerpt from the article published in Frontiers in Pediatrics , 9, 13 December 2021, DOI: Editor’s Highlights Neonatal abstinence syndrome (NAS) is a collection of signs and symptoms commonly observed in […]

Epilepsy in Neurodegenerative Diseases: Related Drugs and Molecular Pathways

By Amanda Cano, Elena Fonseca, Miren Ettcheto, Elena Sánchez-López, Itziar de Rojas, Silvia Alonso-Lana, Xavier Morató, Eliana B. Souto, Manuel Toledo, Mercè Boada, Marta Marquié, and Agustín Ruíz Excerpt from the article published in  Pharmaceuticals. 2021; 14(10):1057. 18 October 2021, DOI: Editor’s Highlights Epilepsy affects approximately 50 million people worldwide. The massive entrance of […]

An Emerging Role for Sigma-1 Receptors in the Treatment of Developmental and Epileptic Encephalopathies

By Parthena Martin, Thadd Reeder, Jo Sourbron, Peter A. M. de Witte, Arnold R. Gammaitoni, and Bradley S. Galer Excerpt from the article published in International Journal of Molecular Sciences 22, no. 16: 8416, 5 August 2021 DOI: Editor’s Highlights Developmental and epileptic encephalopathies (DEEs) are debilitating conditions characterized by recurrent pharmacoresistant seizures of multiple […]

Glioma-Derived TSP2 Promotes Excitatory Synapse Formation and Results in Hyperexcitability in the Peritumoral Cortex of Glioma

By Yao-Hui Wang, Tian-Lan Huang, Xin Chen, Si-Xun Yu, Wei Li, Tao Chen, Yang Li, Yong-Qin Kuang, and Hai-Feng Shu Excerpt from the article published in Journal of Neuropathology & Experimental Neurology, Volume 80, Issue 2, February 2021, Pages 137–149, Editor’s Highlights Seizures are common in patients with brain tumors.  The risk of epilepsy development is […]